Cambridge Cognition Share Discussion Threads

[battlebus2] 06/3/2015 14:27

Thanks davidosh..

[davidosh] 06/3/2015 14:19

An incredibly good and detailed write up over on TMF....

[battlebus2] 04/3/2015 12:43

4 March 2015
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')

US office opened

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, announces the opening of a US office in Salt Lake City to meet the growing demand from both existing and new North American customers. This is a central development for the Company and highlights the Company's strategy to target this market.

The US office will be headed by former Baxter and Myriad executive Bill Rusconi and will support the continuing use of Cantab as the leading cognitive assessments in both pharmaceutical clinical trials and academic research but also increase the global reach of the Company's emerging healthcare technology division.

The cloud-based Cantab Connect range is already used extensively in central nervous system (CNS) drug trials, where the iPad based products have gained widespread acceptance for their ability to deliver rapid, accurate and reproducible clinical measures of cognitive function across multiple sites. However, a growing awareness of the need to assess cognitive performance is contributing to the increased adoption of Cantab technology in pharmaceutical, academic and healthcare sectors.

Commenting on the announcement, Dr Nick Kerton, CEO of Cambridge Cognition said: "The establishment of a US office, with a team providing business development, customer support and cognitive science experience and expertise, is a natural move for Cambridge Cognition. Having a strong US presence will not only enable us to strengthen our leadership in the pharmaceutical clinical trials market, but also to invest in the education and conversion of customers in internationally renowned centres where academic research, clinical development and healthcare diagnostics come together."

[phowdo] 03/3/2015 09:34

Im not expecting too much from these results.
However, I do believe they will be taken over within next few years as their IP is going to become very useful.

Recent Beeb article on governments commitment to dementia research.

[battlebus2] 03/3/2015 09:07

Results Thursday 12th March...

[battlebus2] 21/1/2015 17:15

Finn cap reiterates their buy stance and £1 target today..

[phowdo] 21/1/2015 08:27

Possible one of their clients/potential clients asked them for the iPad integration. Much easier to test people by passing them an iPad than getting them to use a PC/laptop. Much simpler User Interface for the elderly too id imagine.

[battlebus2] 21/1/2015 07:43

New iPad research platform.

[battlebus2] 02/1/2015 09:07

A great start to 2015 here also :))

Bit of a rise before the next news of profitabilty perhaps.

[loobrush] 16/12/2014 18:38

phowdo-you seem to be correct,however on companies website holdings are as follows at 1 Oct.(Does not include Helium)

Major shareholders As at 01 October 2014, shareholders holding more than 3% of the share capital of Cambridge Cognition Holdings plc were:

Name No. of ordinary shares %
Euroblue Investments Limited 3,435,714 20.29%
Octopus Investments Nominees Ltd 3,048,264 18.00%
Michael Buxton 2,889,589 17.07%
Artemis Fund Managers Ltd 714,285 4.22%
AXA Investment Managers UK Ltd 714,285 4.22%
Investment Solutions (SA) 650,000 3.84%
Hargreave Hale 512,376 3.03%
- See more at:
However maybe the Helium holding is Investment solution(SA) anyone an idea about this ?

[phowdo] 16/12/2014 16:22

Its a disposal of the 650k that they acquired back in July.

[loobrush] 16/12/2014 16:12

Rns -this is a NEW investor holding as far as I can see.

[phowdo] 16/12/2014 15:34

Looks like that's the seller cleared.

[battlebus2] 15/12/2014 17:53

Brokers target £1

[loobrush] 15/12/2014 17:52

Directors buying is quite amazing as they have also been granted options only recently as well. Must be something coming up in the new year to prompt this buying. They have stated that they will be profitable next year, maybe the are going to get a rollout deal of their dementia kit with the NHS shortly.
Not many free float shares so a deal could see this motor.
Fingers crossed.

[phowdo] 15/12/2014 09:28

More director buys around the bid on Friday.
There was also a 296k transaction at that price - perhaps Nigel Wray?
Must be clearing a seller at that price anyway.

[battlebus2] 15/12/2014 09:25

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, has been notified of the following transactions by Directors, which took place on 12 December 2014.

Nick Kerton, Chief Executive Officer, purchased 45,615 ordinary shares at a price of 62.19 pence each. Following this notification, Dr Kerton now has a total beneficial interest of 172,900 Ordinary Shares representing 1.02% of the issued share capital of the Company.

Nick Walters, Chief Financial Officer, purchased 27,369 ordinary shares at a price of 62.19 pence each. Following this notification, Mr Walters has a total beneficial interest of 119,369 Ordinary Shares representing 0.71% of the issued share capital of the Company.

Michael Lewis, Chairman, purchased 13,684 ordinary shares at a price of 62.19 pence each. Following this notification, Mr Lewis has a total beneficial interest of 27,969 Ordinary Shares representing 0.17% of the issued share capital of the Company.

Cambridge Cognition's capital consists of 16,930,556 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury.

[battlebus2] 30/10/2014 08:04

Morning janeann. Doing my best thanks.

[janeann] 30/10/2014 07:49

Morning Battlebus. Very positive recognition of Cogs technology. Trust all well.

[battlebus2] 30/10/2014 07:20

Supporting the Dementias Research Platform UK

Cambridge Cognition, (AIM: COG), which specialises in computerised neuropsychological tests, announces that the Company strongly supports the launch of The Medical Research Council ('MRC') Dementias Research Platform UK ('DPUK'). Cambridge Cognition's Cantab Connect is playing a significant role in the ongoing DPUK Dementia Deep and Frequent Phenotyping feasibility study.

This joint-funded National Institute for Health Research ('NIHR') and MRC project for intensive phenotyping of 24 pre-clinical Alzheimer's disease patients, aims to identify biomarkers that change over periods of months, rather than years. The Deep and Frequent Phenotyping study assesses key cognitive domains affected in Alzheimer's disease using Cambridge Cognition's rapid touchscreen cognitive test system, Cantab Connect.

Alongside the cognitive tests, the study uses an extensive range of MR imaging, additional clinical testing and biomarkers, at frequent intervals during the three months study period for each participant. The goal is to identify protocols and biomarkers that will be used in a wide range of follow-on trials

The MRC DPUK is a £53m public-private partnership with World leading researchers from Universities across the UK (Cambridge, Cardiff, Edinburgh, Imperial College, Oxford, Manchester, Newcastle, Swansea and UCL) and six companies (GlaxoSmithKline, Janssen Research & Development, AstraZeneca-MedImmune, Ixico, SomaLogic and Araclon) who will use state of the art technologies such as Cantab Connect to accelerate progress in dementias research. It brings together two million participants aged 50 and over, from 22 existing study groups within the UK, making it the World's largest population study for use in dementias research. The DPUK's aims are early detection, improved treatment and ultimately, prevention, of dementias.

Dr Jenny Barnett, Director of Healthcare Innovation at Cambridge Cognition commented: "We fully support the DPUK initiative and are pleased to see the UK setting a leading example to accelerate early detection of dementia and develop knowledge leading to new diagnostic procedures, drug treatments and other therapies that could prevent or delay the onset and progression of Alzheimer's and other neurodegenerative diseases."

Chief Executive Officer of Cambridge Cognition, Nick Kerton, commented: "This represents the largest population-based study on the progress of dementia. It is a testament to the quality and utility of the products that we have developed that they will be used as an integral part of this study."

[cheshire man] 03/10/2014 13:59

Indeed bb :-)

[battlebus2] 03/10/2014 09:32

Playful that made me chuckle :)))

You know me too well!!
Great to see us get it right again C.M.
And yes still holding.

[loobrush] 03/10/2014 08:30

Not many shares available so one needs to get in quick as could really motor as 20% holder NIgel Wray, renowned investor, will have plans to make this a big company.

[playful] 03/10/2014 07:57

He will be itching to comment as I’m certain this will not be a share he sold.

[cheshire man] 03/10/2014 07:25

Another lift this morning I see,,,,,,,wonder where battlebus is ?